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ABSTRACT 46 
Predicting mobilization failure before it starts may enable patient-tailored strategies. Although 47 
consensus criteria for predicted PM (pPM) are available, their predictive performance has never 48 
been measured on real data. We retrospectively collected and analyzed 1318 mobilization 49 
procedures performed for MM and lymphoma patients in the plerixafor era. In our sample, 50 
180/1318 (13.7%) were PM. The score resulting from published pPM criteria had sufficient 51 
performance for predicting PM, as measured by AUC (0.67, 95%CI: 0.63-0.72). We developed a 52 
new prediction model from multivariate analysis whose score (pPM-score) resulted in better AUC 53 
(0.80, 95%CI: 0.76-0.84, p<0001). pPM score included as risk factors: increasing age, diagnosis of 54 
NHL, positive bone marrow biopsy or cytopenias before mobilization, previous mobilization 55 
failure, priming strategy with G-CSF alone or without upfront plerixafor. A simplified version of 56 
pPM-score was categorized using a cut-off to maximize positive likelihood ratio (15.7, 95%CI: 9.9–57 
24.8); specificity was 98% (95%CI: 97%-98.7%), sensitivity 31.7% (95%CI: 24.9%-39%); positive 58 
predictive value in our sample was 71.3% (95%CI: 60%-80.8%). Simplified pPM-score can “rule in” 59 
patients at very high risk for PM before starting mobilization, allowing changes in clinical 60 
management, such as choice of alternative priming strategies, to avoid highly likely mobilization 61 
failure. 62 
63 
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Introduction 64 
High dose chemotherapy followed by autologous stem cell rescue is a mainstay of treatment for 65 
Multiple Myeloma (MM), Non Hodgkin Lymphoma (NHL) and Hodgkin Disease (HD). Autologous 66 
stem cell transplant (auto-SCT) is almost exclusively performed today with peripheral blood stem 67 
cells (PBSCs) infusion; 1 therefore stem cell mobilization (SCM) currently represents a crucial step 68 
of the whole transplant process. A threshold of 2x106CD34+/Kg is regarded by most centers as the 69 
minimum amount of PBSCs to be infused to in order to safely perform the auto-SCT procedure.2 70 
Despite developments in SCM protocols, a proportion of patients between 5% and 30% fail to 71 
collect an adequate number of CD34+.3,4,5,6,7 Poor mobilization forces the patient to undergo a re-72 
mobilization procedure and in some cases leads to postponing or even abandoning a transplant 73 
strategy. Several factors have been associated with poor mobilization,4,5,8,9,10,11,18,12  however a 74 
thorough profile of the patient at high risk of sub-optimal SCM is still missing. 75 
The Gruppo Italiano Trapianto Midollo Osseo (GITMO) has recently proposed a definition of the 76 
‘proven poor mobilizer (PPM) and the predicted poor mobilizer (pPM), adopting a consensus based 77 
on an analytic hierarchy process (AHP).13 While the GITMO definition of the PPM appears 78 
straightforward and is currently adopted by most European centers, identification of pPM appears 79 
more nuanced, and the GITMO pPM criteria should be validated in clinical trials and common 80 
clinical practice.  81 
Early identification of mobilization failure is even more important nowadays, given the availability 82 
of interventions to boost or rescue low-performing procedures, such as the CXCR4 antagonist 83 
plerixafor. Currently, low circulating CD34+ count before apheresis is widely accepted as the 84 
stronger parameter able to predict mobilization failure. Thus, to assist the clinician in a timely and 85 
cost-effective use of Plerixafor, various algorithms were developed, based on the circulating 86 
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CD34+ at day 4 (in case of steady-state mobilization) or at the time of white blood cell (WBC) 87 
recovery (in case of chemo-mobilization).14,15 However, such algorithms are applicable belatedly, 88 
only a few hours before the apheresis procedure begins. Ideally, identification of patients at high 89 
risk of inadequate SCM should be performed before starting the mobilization process, and 90 
protocol planning should be individualized according to patient and disease characteristics, and to 91 
stem cell target dose. Such tailored approach might help to optimize resources management, 92 
avoiding suboptimal stem cell collection, need for re-mobilization, and redundant days of 93 
apheresis.  94 
We therefore conducted this retrospective study with the aim to validate the predictive ability of 95 
GITMO criteria for pPM, by measuring their diagnostic accuracy for the outcome of mobilization 96 
failure. Furthermore, by analyzing SCM kinetics in a large cohort of myeloma and lymphoma 97 
patients, we aimed to improve their predictive ability by adding new data, in order to elaborate a 98 
“poor mobilization risk score” easily applicable in the everyday practice, to help decision-making 99 
and procedure customization based on pre-mobilization parameters. 100 
Methods 101 
This was a multicenter retrospective observational study involving 17 Italian GITMO centers. The 102 
protocol was approved by the Ethics Committee of Potenza and subsequently by all participating 103 
centers. A waiver of patient’s informed consent was obtained, owing to the retrospective nature 104 
of the study and provided that all patients’ data were collected and managed after being 105 
anonymized. The study was conducted in accordance to Helsinki declaration, Good Clinical 106 
Practice and of applicable national regulations. All Centers were asked to fill a database containing 107 
informations on all mobilization attempts performed between Jan 1st 2009 and Jan 31st 2014 in 108 
patients with Multiple Myeloma (MM), Hodgkin’s (HL) and non-Hodgkin’s Lymphomas (NHL). 109 
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Collected data pertained to patient’s characteristics, underlying hematological disease, 110 
therapeutic history before mobilization and kinetics and results of the mobilization process; data 111 
collection was arranged in order to evaluate the presence or absence of GITMO criteria for pPM. 112 
Statistics 113 
The relevance of the candidate predictive factors was evaluated using univariate logistic 114 
regression for the outcome variable of pPM. Subsequently, multiple logistic regression with 115 
backward variable selection was performed to identify independent predictive factors. Explored 116 
variables are reported in table 1. WBC and absolute neutrophil counts were analyzed on the log-117 
scale because of highly skewed distributions. Continuous parameters were not categorized a 118 
priori because this would have negatively affected the power of the analysis. Values of non-119 
dichotomous categorical variables were transformed in dummy variables for the purpose of the 120 
analysis. 121 
The outcome variable was the failure of a mobilization attempt defined according to the GITMO 122 
criteria for proven poor mobilizer. To this end, in patients treated with Plerixafor on demand, the 123 
data collected reflected the situation after the declaration of failure (i.e declining CD34+ cell count 124 
with a peak value <20/mcl or at least 3 aphereses with total collection <2 x 106 CD34/kg) and 125 
before Plerixafor administration. Conversely, patients treated with upfront Plerixafor had their 126 
data collected at the end of the mobilization process, as for all other patients. 127 
To estimate the discriminating power of a chosen model, a receiver operating characteristic (ROC) 128 
curve was plotted. The areas under the ROC curves (AUCs) were calculated as previously 129 
described16. AUC comparisons were performed according to the method described by DeLong et 130 
al.17 131 
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Internal validation was performed applying the refined bootstrap described by Efron.18 Random 132 
data splitting in training and validation sample was not performed because this internal validation 133 
procedure reduces the power for both model development and validation and is known to be 134 
inferior to bootstrap validation. Bootstrap validation used the AUC as performance index. 135 
Two groups were defined by categorizing the score (linear predictor) of the final logistic 136 
regression model. For each cut-off, sensitivity, specificity, PPV, and NPV were calculated as simple 137 
proportions with 95% confidence intervals (CI). Likelihood ratios and their CI were calculated as 138 
ratios between proportions. The McNemar chi-square test was used to compare sensitivity and 139 
specificity between assays among failures and non-failures, respectively.19 Cutpoint selection was 140 
based on clinical criteria: the purpose of the clinical tool for PPM prediction was to identify 141 
patients at very high risk for mobilization failure in order to support a practice-changing clinical 142 
decision. Therefore we aimed to maximize positive likelihood ratio (LR+) over negative likelihood 143 
ratio (LR-), by achieving a +LR value >10. 144 
An explorative simplification of the final model was developed using basic mathematical 145 
operations. Spearman’s rho was calculated to measure the correlation between the original score 146 
and the simplified version.20 147 
Sample size calculation was based on AUC for the outcome variable of failed mobilization attempt 148 
(PPM): assuming a prevalence of PPM equal to 0.2, data from 845 mobilizations (169 failures) had 149 
to be collected to obtain an AUC≥ 0.57 (alpha=0.05 and power=0.8); with different PPM 150 
prevalences (0.1-0.5), the total number of mobilization attempts to be collected ranged from 530 151 
to 1600. 152 
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Statistical analyses were performed using Stata 12 (Statacorp, College Station, Texas) and 153 
MedCalc (MedCalc Software, Ostend, Belgium). Significance level was 0.05 for all analyses. 154 
 155 
Results 156 
Patient characteristics 157 
We analyzed data from 1318 mobilization attempts. Disease distribution was the following: 600 158 
(46%) patients were affected by MM, 554 (42%) by NHL and 164 (12%) by HL. Median age at 159 
diagnosis was 56 years (range 5-76 years); four patients had less than 14 years at diagnosis but 160 
underwent mobilization after this age; 56% of patients were male. Sixty percent of patients had 161 
been treated with a single chemotherapy course before mobilization, 31% with 2 courses and 8% 162 
with 3 or more. Twelve percent of patients had been subjected to treatments potentially harmful 163 
to SCM (fludarabine, lenalidomide, radio-immunoconjugates, melphalan, carmustine); extensive 164 
radiotherapy on marrow bearing tissue had been used in 23 patients (1.7%). Before the 165 
mobilization attempt, 81% of patients were in partial or complete response; BM biopsy (BMB) was 166 
negative in 62% and showed extensive infiltration (≥30% of total cellularity) in 3% of patients. Pre-167 
mobilization BMB was omitted in 199 patients, due to different centers’ policies (3 centers did not 168 
perform it routinely before mobilization). 169 
Priming strategies involved the use of chemotherapy plus G-CSF in 94% of patients; chemotherapy 170 
protocols were quite disease-specific: cyclophosphamide was employed mostly in MM patients, 171 
while Ara-C containing regimens were preferred in NHL. Upfront plerixafor was added to the 172 
mobilization regimen in 44 patients (3%). Ninety-eight patients (7.4%) started SCM with at least 173 
one severe cytopenia (≥ grade 3 anemia, thrombocytopenia or neutropenia). 174 
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Overall, 180 patients (13.7%) failed the mobilization attempt, according to GITMO criteria for 175 
PPM. Failure resulted exclusively from inadequate CD34+ cells mobilization (peak CD34 count 176 
<20/mcl) in 36 cases (20%), from insufficient harvest (total CD34 ≤2 x 106/kg) in 17 cases (9.4%) 177 
and from both criteria in 127 cases (70.6%). Further basal characteristics are reported in table 1. 178 
 179 
Validation of the GITMO criteria 180 
To verify the actual consistency of GITMO consensus, we retrospectively applied the criteria to 181 
our cohort of 1318 cases. For each case, a score was generated (pPM-GITMO score) by summing 1 182 
point for each minor criteria and 2 points for each major criteria that were present. The only 183 
criterion considered in the original publication that could not be ascertained was BMB cellularity 184 
before mobilization, given the high rate of missing values. 185 
This score ranged from 0 to 7 and the median value was 1. The AUC relative to the outcome of 186 
proven poor mobilizer was 0.673 (95%CI: 0.627-0.719, Fig. 1A). According to the GITMO 187 
consensus, the definition of pPM required at least one major criterion or two minor criteria; 188 
hence we considered a cut-off equal of greater than 2 for the pPM-GITMO score to be predictive. 189 
With this cut-off (Table 2), the sensitivity for the diagnosis of pPM was 53.3% (95%CI: 45.8%-190 
60.8%) and the specificity 73.8% (95%CI: 71.2%-76.3%); LR+ was 2.04 (95%CI: 1.72-2.41). Given 191 
the prevalence of proven poor mobilizer observed in our cohort (13.7%), the PPV resulted 24.4% 192 
(95%CI: 20.2%-28.9%). 193 
We implemented exploratory analyses to improve the predictive performance of the GITMO-pPM 194 
score. Increasing the cut-off to values equal or greater than 3 yielded a significantly lower 195 
sensitivity (39.4%) but higher specificity (90.8%); the PPV was 40.3% (95%CI: 33%-48%). 196 
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In the GITMO consensus, the splitting into major and minor criteria represented a simplification of 197 
the weights derived from AHP; thus we checked whether using the original AHP weights could 198 
improve the predictive performance of the GITMO-pPM score. Therefore we generated a score 199 
(AHP-pPM score) by summing the relative weight of each criterion as reported in the original 200 
publication. This score ranged from 0 to 0.55, had median value of 1 and produced an AUC of 201 
0.679 (95%CI: 0.634-0.725, Fig. 1B). To maximize specificity and LR+, we chose a cut-off equal of 202 
greater than 0.21 (Table 2), yielding a sensitivity of 33.3% (95%CI: 26.5%-40.7%) and a specificity 203 
of 93.1% (95%CI: 91.4%-94.5%); LR+ was 4.8 (95%CI: 3.57-6.46); PPV was 43.2%% (95%CI: 34.8%-204 
51.8%). 205 
Predictive factors for poor stem cell mobilization 206 
Sex, BMB at diagnosis and previous radiotherapy (local or extensive) did not show predictive 207 
relevance for mobilization failure in univariate analyses (Table 3). Among non-dichotomous 208 
categorical variables, BMB before mobilization had a significant protective effect if pathologic 209 
infiltration was absent, while it favored failure when disease infiltration reached 30% or more. 210 
NHL was strongly associated with failure, while HL was the opposite, and MM was non-significant; 211 
among priming strategies, use of G-CSF alone had strong impact on failure, while other 212 
chemotherapy regimens were not significant. Increasing age, number of full chemotherapy 213 
courses, previous use of fludarabine, lenalidomide, melphalan and carmustine, previous 214 
mobilization failure, refractory disease, and lower CBC values before mobilization, all had 215 
significant negative impact on the main outcome; upfront plerixafor use was instead associated 216 
with a reduced probability of failure. 217 
Predicted Poor Mobilizer (pPM) score 218 
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Hodgkin’s lymphoma, refractory disease, absent pathologic infiltration at pre-mobilization BMB 219 
lost predictive relevance when evaluated in multivariate analysis. Continuous variables were 220 
categorized to help their potential application in clinical practice. For the same reason, the 4 221 
variables reporting for previous use of fludarabine, lenalidomide, melphan and carmustine were 222 
merged in one binary variable encoding for patients undergoing at least one of those treatment at 223 
risk. In the final model (Table 4), the following variables were identified as independent predictive 224 
factors for mobilization failure: increasing age (from ≤45 years to 46-60 years and to >60 years), 225 
diagnosis of NHL, disease infiltration ≥ 30% at the pre-mobilization BMB, previous mobilization 226 
failure, increasing number of full chemotherapy courses, previous treatment at risk (fludarabine, 227 
lenalidomide, melphan or carmustine), reduced hemoglobin (from >130 g/l to 80-130 g/l to less 228 
than 80 g/l), low WBC count (<5 x 109/L), low Plt count (<170 x 109/L), use of G-CSF alone as a 229 
priming strategy and not providing upfront Plerixafor. The predicted poor mobilizer score (pPM 230 
score) was calculated as shown in Table 5. 231 
Predicted poor mobilizer score ranged from 2.46 to 12.82, had median value of 5.78 and 232 
produced an AUC of 0.801 (Fig. 1C; 95%CI: 0.764-0.838, Fig. 1C). We chose a cut-off >7.862 (Table 233 
2), yielding a specificity of 97.4% (95%CI: 96.3%-98.2%) and a sensitivity of 32.8% (95%CI: 26%-234 
40.2%); LR+ was 12.43 (95%CI: 8.25-18.74), PPV was 66.3% (95%CI: 55.5%-76%). 235 
The probability of mobilization failure according to the pPM score can be calculated as: 236 
ܲݎ݋ܾܾ݈ܽ݅݅ݐݕ = ݁
(௣௉ெ௦௖௢௥௘ି଼.ଶସହ)
݁(௣௉ெ௦௖௢௥௘ି଼.ଶସହ) + 1 
The internal validation procedure correcting for overoptimism by bootstrap showed stability of 237 
predictive performance measured with AUC values (Table 6). 238 
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Simplified predicted Poor Mobilizer score 239 
The classification according to the pPM-score involves some mathematical operations best 240 
performed using an electronic calculator. To make the score most practicable, we exploratively 241 
simplified it by rounding the weights of each factor to multiple of 0.5 points. This score was 242 
calculated as shown in Table 5. 243 
The simplified version of the pPM score was highly correlated with the original one (Spearman’s 244 
rho =0.983, p <0.0001). Simplified pPM score ranged from 2 to 10, had median value of 4.5 and 245 
produced an AUC of 0.795 (Fig. 1D; 95%CI: 0.757-0.833, Fig. 1C). We chose a cut-off ≥ 6.5 (Table 246 
2), yielding a specificity of 98% (95%CI: 97%-98.7%) and a sensitivity of 31.7% (95%CI: 24.9%-247 
39%); LR+ was 15.7 (95%CI: 9.9-24.8); PPV was 71.3% (95%CI: 60%-80.8%).  248 
Score comparison 249 
The AUC of the 4 different scores were compared: GITMO-pPM and AHP-pPM score had both a 250 
significantly inferior AUC than pPM score and simplified pPM-score (p<0.0001 for all comparisons). 251 
There were no significant differences between GITMO-pPM and AHP-pPM score (p =0.40) and 252 
between pPM score and simplified pPM-score (p =0.08). Detailed results are reported in Tab S2. 253 
We next compared the sensitivity and specificity of the different scores according to the chosen 254 
cut-offs: GITMO-pPM score with cut-off ≥ 2 had the best sensitivity compared to all alternatives; 255 
simplified pPM score with cut-off ≥ 6.5 had the best specificity with respect to all other models 256 
and cut-offs. Detailed results are reported in Tab S2. 257 
Discussion 258 
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In this retrospective study, we collected a representative sample of mobilization outcomes in the 259 
plerixafor era in MM and lymphoma patients. The analysis of this large database aimed: 1-to 260 
validate published GITMO criteria for pPM (which were developed by AHP consensus method) on 261 
strong clinical data; 2-to improve the predictive ability of these criteria, by adding new variables 262 
and refining weights of already present criteria. The ultimate objective was to develop a 263 
standardized clinical tool able to identify “a priori” those patients at very high risk of failure, 264 
before starting the mobilization procedure, in order to drive a practice-changing clinical decision. 265 
Performance measures for prediction of mobilization failure were derived for 4 different models: 266 
(1) based on the original GITMO criteria (GITMO-pPM score); (2) using original AHP weights of 267 
GITMO criteria (AHP-pPM score); (3) a new model derived through multivariate regression analysis 268 
(pPM score); (4) a simplified version of this new model (simplified pPM score). The original GITMO 269 
criteria had modest performance measured by AUC (0.67); when applied with the proposed cut-270 
off for pPM, it had limited sensitivity (53%) and modest specificity (74%) and use of original AHP 271 
weights did not improve their predictive performance. The new model (pPM-score) had far better 272 
AUC (0.80); its simplified version (ranging from 2 to 10) was categorized using a cut-off to 273 
maximize specificity: indeed in our sample, a high proportion of patients with simplified pPM-274 
score >6.5 failed the mobilization (PPV =71%). Simplified pPM-score, combining unmodifiable 275 
patient-related factors with clinical choice-dependent variables, can be easily simulated before 276 
starting SCM, therefore supporting patient-tailored mobilization strategies.. 277 
 Today, the first key decision in scheduling a first-line SCM regimen is the choice between a 278 
chemo-mobilization or a cytokine-only strategy. The second crucial stage is the dynamic 279 
identification of those patients, during SCM, in whom the addition of just-in-time plerixafor could 280 
be useful and cost-effective. To this end, different algorithms have been proposed:20,21,22 all of 281 
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them include PB CD34+ cell count, the most reliable parameter to trigger plerixafor 282 
administration.23,24 Other parameters proposed include WBC and platelet counts as surrogates of 283 
hematopoietic recovery, collection target dose and first day of apheresis yield.9 Nevertheless, such 284 
algorithms present several limits. First of all, circulating CD34+ threshold values used to trigger 285 
plerixafor administration present a significant variability between different studies, ranging from 286 
727 to 109,15 or 20/mcl.25 Secondly, most of those algorithms were not validated outside the 287 
institution they were developed, making problematic their application to other centers, as 288 
significant differences exist in facilities, staff, skills and procedures. In addition, many algorithms 289 
leave unresolved a “gray zone” with intermediate values of PB CD34+ (i.e. 10-20/mcl), where no 290 
recommendations are drawn and a “case by case” approach is suggested. The EBMT 291 
recommendations26 recognized this window of uncertainty and proposed to fill the gap with a 292 
clinical decision taking into account risk factors for poor mobilization. Although these 293 
recommendations acknowledged first the role of patient and disease-related risk factors in the 294 
decision-making of mobilization, the choice was left to individual discretion. Recently published US 295 
recommendations27 suggest as well to tailor the mobilization plan according to patient and disease 296 
characteristics; in case of MM, the authors suggest chemo-mobilization (instead of steady-state 297 
strategy) for patients previously treated with lenalidomide or melphalan, or having received more 298 
than 1 previous line of therapy. Similarly, for patient with lymphoma, the authors recommend to 299 
limit steady-state mobilization to patients “at low risk for mobilization failure”; once again, an 300 
explicit and reproducible clarification of the “risk of failure” is missing.  301 
In 2012 a GITMO panel of experts proposed definitions for PM, recognizing two clearly different 302 
categories: the one of proven PM, which referred to a completed process merely requiring 303 
uniform and detailed characterization; the other one of predicted PM, i.e. a new classification of 304 
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patients expected to be at higher risk of failure for future mobilizations. Although application of 305 
AHP methodology to complex issues demonstrated excellent results even when consistent data 306 
were unavailable28, the adoption of a predictive model in a clinical setting requires nonetheless 307 
validation on real life patients. To verify the actual consistency of GITMO consensus, we 308 
retrospectively applied the criteria to our cohort of 1318 cases and measured their predictive 309 
performance with the AUC. Although no single measure of diagnostic accuracy fully captures the 310 
clinical value of a test, AUC is considered a valuable estimate of the global discriminative power, 311 
being independent from the chosen cut-off and from the disease prevalence.29 Although the 312 
threshold to reach our predefined endpoint was set low (0.57), the obtained value (0.67) is 313 
considered indicative of sufficient diagnostic accuracy.  314 
To gain a significant improvement over the GITMO criteria, we elaborated a new score based on 315 
data collected in our large database, evaluating all variables originally considered by the GITMO 316 
consensus and new ones: several risk factors previously identified by the Consensus were 317 
confirmed as relevant, such as stem cell poisons (e.g. lenalidomide and fludarabine). Instead, the 318 
role of extensive radiotherapy (previously considered major criterion) did not emerge as 319 
statistically significant, probably due to the very low number of patients who actually received it. 320 
Finally, a relevant statistical weight emerged for blood counts of all lineages, which adds to 321 
confirmation of other factors already identified by the Consensus (neoplastic BM involvement and 322 
previous chemotherapy burden), to allow detailed characterization of the BM functional reserve 323 
with simple parameters. 324 
The pPM score undoubtedly improved the diagnostic accuracy with respect to GITMO criteria. 325 
However, improvements in test accuracy will not benefit patients unless they lead to changes in 326 
patient management.30 To reach this goal, a clinical test should be easily applied and interpreted. 327 
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The pPM score contains predictors that are known before starting SCM: some pertain to patients’ 328 
history, others to procedures routinely performed in the clinical practice (CBC, BMB), others to the 329 
mobilization planning. Algorithms based on PB CD34+ cell count only allow a late-stage clinical 330 
decision, when the mobilization process is already close to the end and only limited action 331 
(addition of just-in-time plerixafor) is possible. A finer and earlier planning would add a 332 
significantly wider range of possibilities to improve mobilization outcomes (table 7). To enhance 333 
feasibility of pPM-score, we created a simplified version, easily computable without an electronic 334 
calculator. Furthermore, we decided to dichotomize simplified pPM-score, aiming to make it a 335 
“ruling-in” diagnostic test. To this end we chose to maximize the LR+, albeit preserving a sensitivity 336 
≥30%. Many useful properties make LR+ suitable to this scope31: LR+ is independent of the disease 337 
prevalence in the examined group, making it immediately applicable to other clinical settings; LR+ 338 
is considered the best indicator for ruling-in diagnosis: the higher the LR+, the greater is the shift 339 
of the probability of disease. Good diagnostic tests have LR+ >10 and their positive result has a 340 
significant contribution to the diagnosis. The simplified pPM-score with a cut-off ≥6.5 had a LR+ of 341 
15.7: in our sample, this means that positive patients have their probability of failure increased 342 
from 13.7% to 71.3%, therefore requiring alternative strategies to avoid highly likely failure. One 343 
option is tailoring the priming strategy: the eternal dispute between steady-state and chemo-344 
mobilization would be resolved if we could appropriately personalize mobilization strategies. Our 345 
results clearly support the use of chemo-mobilization in pPM, confirming a growing body of 346 
evidence.32 Second, we provide a strong suggestion for upfront use of Plerixafor in pPM. 347 
Interestingly, very recently Yuan and colleagues33 reported the results of the mobilization policy 348 
implemented in their center in Duarte, California. They propose the administration of upfront 349 
plerixafor in patients defined as “predicted poor mobilizers” according to criteria similar to ours, 350 
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and in MM patients candidates for tandem auto-SCT. Alternatively, the pPM-score can be 351 
integrated in algorithms based on PB CD34+ cell count, to resolve their “gray zones”, thus 352 
justifying earlier addition of Plerixafor. Finally, recognizing in advance pPMs will enable a special 353 
surveillance on them during the mobilization process, allowing for several technical optimizations 354 
such as use of large volume apheresis or starting apheresis with lower CD34+ thresholds (table 7). 355 
Maximization of the LR+ implied an obvious reduction of the sensitivity (32% using cut-off ≥6.5): 356 
this important limitation should be taken into account if simplified pPM-score is used for clinical 357 
decisions. Negative patients should still be considered at risk for mobilization failure. In this group, 358 
we suggest careful monitoring of mobilization kinetics and application of algorithms for “just-in-359 
time” Plerixafor to rescue additional patients from mobilization failure. 360 
Another important issue to be considered when applying the pPM-score is that minimum dose of 361 
CD34+ is not equivalent to target dose: in our analysis, failure was defined as collection of less 362 
than 2 x106 CD34+/kg. However, in the clinical practice, definition of failure should be related to 363 
patient’s goals: as an example, collection of 3 x 106 CD34+/kg is clearly unsatisfactory if a double 364 
auto-SCT is planned. 365 
In conclusion, we have built on real large representative data a score to “rule in” patients at very 366 
high risk for PM before starting mobilization, allowing changes in clinical management, to avoid 367 
highly likely mobilization failure. To achieve the highest possible power from the available data, 368 
we performed internal validation by bootstrap,34 thus confirming a high stability of the developed 369 
predictive model. Nevertheless, an external validation on an independent data set is still required 370 
to allow a broad application of this clinical tool. Finally, given the retrospective and observational 371 
nature of this study, it should be reminded that changes of SCM strategies which may be 372 
17 
 
suggested by pPM-score application (table 7), although reasonable, warrant to be tested in a 373 
prospective interventional trial to demonstrate clinical effectiveness. 374 
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Figure Legends 
Figure 1: Area Under the Receiving Operating Characteristic (ROC) Curve (AUC) for the outcome of proven poor 
mobilizer and the 4 scores generated (A: GITMO-PPM score; B: AHP-PPM score; C: PPM score; D: simplified 
PPM score).  
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Table I: Basal characteristics 
BASAL CHARACTERISTICS ALL PATIENTS MM NHL HL
Age at diagnosis, median (range) 55.6 (4.6 - 76.5) 59 (18 - 74) 54 (5 - 76) 37 (5 - 76) 
 ≤45 337 (26%) 57 (10%) 166 (30%) 114 (70%) 
 45-60 571 (43%) 293 (49%) 246 (44%) 32 (20%) 
 > 60 410 (31%) 250 (42%) 142 (26%) 18 (11%)
Sex     
 Male 753 (57%) 321 (54%) 346 (62%) 86 (52%) 
 Female 565 (43%) 279 (47%) 208 (38%) 78 (48%) 
Disease 
 Multiple Myeloma 600 (46%)    
 Non-Hodgkin’s Lymphoma 554 (42%)    
 Hodgkin’s Lymphoma 164 (12%)    
Bone marrow infiltration at diagnosis 
 Absent 499 (38%) 18 (3%) 332 (60%) 149 (91%) 
 Present: < 30% 306 (23%) 174 (29%) 121 (22%) 11 (7%) 
 Present: ≥ 30% 511 (39%) 407 (68%) 100 (18%) 4 (2%)
 Unknown 2 (0.2%) 1 (0.2%) 1 (0.2%) 0 (0%) 
PREVIOUS TREATMENTS     
Number of chemotherapy courses - median (range) 1 (1 - 6) 1 (1 - 6) 2 (1 - 6) 2 (1 - 5) 
 1 790 (60%) 489 (82%) 259 (47%) 42 (26%)
 2 413 (31%) 79 (13%) 230 (42%) 104 (63%) 
 3 93 (7%) 21 (4%) 57 (10%) 15 (9%) 
 ≥4 22 (2%) 11 (2%) 8 (1%) 3 (2%) 
Use of myelotoxic agents (at least one) 153 (12%) 133 (22%) 15 (3%) 5 (3%)
 Fludarabine 12 (1%) 1 (0.2%) 8 (1%) 3 (2%) 
 Lenalidomide (≤ 4cycles / > 4 cycles) 114 (9%) / 7 (1%) 113 (19%) / 7 (1%) 1 (0.2%) / 0 (0%) 0 (0%) / 0 (0%) 
 Radioimmunoconjugates 1 (0.1%) 1 (0.2%) 0 (0%) 0 (0%) 
 Melphalan 27 (2%) 20 (3%) 5 (1%) 2 (1%)
 BCNU 9 (1%) 2 (0.3%) 5 (1%) 2 (1%) 
 Radiotherapy (limited / extensive) 122 (9%) / 23 (2%) 42 (7%) / 21 (4%) 37 (7%) / 6 (1%) 43 (26%) / 5 (3%) 
Bone marrow infiltration before mobilization
 Absent 821 (62%) 201 (34%) 471 (85%) 149 (91%) 
 Present: < 30% 263 (20%) 231 (39%) 26 (5%) 6 (4%)
 Present: ≥ 30% 35 (3%) 30 (5%) 5 (1%) 0 (0%) 
 Unknown 199 (15%) 138 (23%) 52 (9%) 9 (5%) 
Disease status at mobilization     
 Remission (complete or partial) 1066 (81%) 535 (89%) 426 (77%) 105 (64%)
 Refractory 242 (18%) 63 (11%) 121 (22%) 58 (35%) 
 Unknown 10 (1%) 2 (0.3%) 7 (1%) 1 (1%) 
Failed previous mobilization attempt 94 (7%) 37 (6%) 51 (9%) 6 (4%) 
  
MOBILIZATION     
Blood count values before starting mobilization     
 Hemoglobin (g/dl) - median (range) 11.8 (7.2 - 19.8) 12.2 (7.2 - 18.8) 11.3 (7.2 - 17.3) 11.6 (7.9 - 16.2)
 Leukocytes (x 10^9/L) - median (range) 5.2 (0 - 426) 5.3 (0.3 - 42.6) 4.9 (0 - 58.27) 5.8 (0.9 - 22.8) 
 Neutrophils (x 10^9/L)  - median (range) 3.2 (0 - 282) 3.1 (0.1 - 28.2) 3.1 (0 - 45.2) 3.9 (0.1 - 18.7) 
 Platelets (x 10^9/L)  - median (range) 223 (6 - 1167) 230 (6 - 665) 202 (6 - 1167) 239 (7 - 601) 
Mobilization regimen 
 High dose CTX (2-7 g/mq) + G-CSF 650 (49%) 499 (83%) 131 (24%) 20 (12%) 
 DHAP + G-CSF 126 (10%) 6 (1%) 101 (18%) 19 (12%) 
 IEV + G-CSF 70 (5%) 0 (0%) 21 (4%) 49 (30%) 
 High dose Ara-C + G-CSF 107 (8%) 4 (1%) 100 (18%) 3 (2%)
 Other chemotherapy regimen + G-CSF 292 (22%) 43 (7%) 177 (32%) 72 (44%) 
 G-CSF alone 73 (6%) 48 (8%) 24 (4%) 1 (1%) 
Dose of G-CSF (μg/kg)     
 5 904 (69%) 332 (55%) 441 (80%) 131 (80%) 
 10 413 (31%) 267 (45%) 113 (20%) 33 (20%) 
 15 1 (0.1%) 1 (0.2%) 0 (0%) 0 (0%)
Plerixafor administered (upfront) 44 (3%) 18 (3%) 24 (4%) 2 (1%) 
Peak CD34+ value (cells/mcl)  - median (range) 85 (0 - 1942) 89 (0 - 971) 76 (0 - 1942) 107 (0 - 1231) 
 <5 61 (5%) 20 (3%) 36 (6%) 5 (3%) 
 <20 163 (12%) 66 (11%) 89 (16%) 8 (5%)
Number of aphereses  - median (range) 1 (0 - 6) 2 (0 - 6) 1 (0 - 5) 1 (0 - 5) 
 >3 47 (4%) 32 (5%) 10 (2%) 5 (3%) 
Total harvest (x 10^6 CD34+/kg)  - median (range) 8.9 (0 - 63.5) 10.1 (0 - 44) 7.6 (0 - 63.5) 9.1 (0 - 47.9)
 <1 118 (9%) 47 (8%) 64 (12%) 7 (4%) 
 <2 144 (11%) 59 (10%) 76 (14%) 9 (5%)
 2 – 5 204 (15%) 87 (15%) 93 (17%) 24 (15%) 
 >5 970 (74%) 454 (76%) 385 (69%) 131 (80%) 
Failed mobilization 180 (14%) 75 (13%) 95 (17%) 10 (6%) 
 Due to low CD34+ peak count 163 (12%) 66 (11%) 89 (16%) 8 (5%)
 Due to insufficient harvest 144 (11%) 56 (9%) 76 (14%) 9 (5%) 
 Due to both above criteria 127 (10%) 50 (8%) 70 (13%) 7 (4%) 
 
Table II: Measures of sensitivity, specificity, positive (LR+) and negative (LR-) likelihood ratio, diagnostic odds ratio, positive (PPV) and negative (NPV) predictive 
values for selected cut-offs of the 4 scores generated to predict mobilization failure. 
 GITMO-PPM score AHP-PPM score PPM score Simplified PPM score 
Cut-off ≥ 2 ≥ 3 ≥ 0.21 > 7.48 > 7.862 ≥ 6 ≥ 6.5
Sensitivity (SE) 0.533 (0.458 - 0.608) 0.394 (0.323 - 0.47) 0.333 (0.265 - 0.407) 0.4 (0.328 - 0.476) 0.328 (0.26 - 0.402) 0.411 (0.338 - 0.487) 0.317 (0.249 - 0.39) 
Specificity (SP) 0.738 (0.712 - 0.763) 0.908 (0.889 - 0.924) 0.931 (0.914 - 0.945) 0.952 (0.938 - 0.963) 0.974 (0.963 - 0.982) 0.947 (0.933 - 0.96) 0.98 (0.97 - 0.987) 
Positive Likelihood Ratio (LR+) 2.04 (1.72 - 2.41) 4.28 (3.31 - 5.53) 4.8 (3.57 - 6.46) 8.28 (6.05 - 11.33) 12.43 (8.25 - 18.74) 7.8 (5.76 - 10.55) 15.67 (9.91 - 24.77) 
Negative Likelihood Ratio (LR-) 0.63 (0.54 - 0.74) 0.67 (0.59 - 0.75) 0.72 (0.65 - 0.8) 0.63 (0.56 - 0.71) 0.69 (0.62 - 0.76) 0.62 (0.55 - 0.7) 0.7 (0.63 - 0.77) 
Diagnostic Odds Ratio 3.22 (2.34 - 4.44) 6.41 (4.47 - 9.18) 6.7 (4.57 - 9.84) 13.13 (8.79 - 19.62) 18.01 (11.2 - 28.96) 12.54 (8.46 - 18.59) 22.47 (13.42 - 37.58) 
Positive predictive value (PPV) 0.244 (0.202 - 0.289) 0.403 (0.33 - 0.48) 0.432 (0.348 - 0.518) 0.567 (0.476 - 0.655) 0.663 (0.555 - 0.76) 0.552 (0.464 - 0.638) 0.713 (0.6 - 0.808) 
Negative predictive value (NPV) 0.909 (0.889 - 0.927) 0.905 (0.886 - 0.921) 0.898 (0.88 - 0.915) 0.909 (0.892 - 0.925) 0.902 (0.884 - 0.918) 0.91 (0.893 - 0.926) 0.901 (0.883 - 0.917) 
 
 
Table III: Association to mobilization failure according to univariate logistic regression 
Candidate predictive factor Odds ratio (95% CI) Probability (Wald test) 
Age (years) 1.01 (1 - 1.03) 0.033 
Sex (female) 1.23 (0.89 - 1.68) 0.204 
Disease   
 MM 0.83 (0.61 - 1.15) 0.264 
 NHL 1.65 (1.21 - 2.27) 0.002 
 HL 0.38 (0.19 - 0.73) 0.004 
BMB at diagnosis   
 Absent 0.99 (0.72 - 1.37) 0.967 
 <30% 0.71 (0.48 - 1.06) 0.094 
 ≥ 30% 1.27 (0.93 - 1.75) 0.135 
Number of chemotherapy courses 2.03 (1.69 - 2.45) <0.001 
Previous use of BCNU 5.15 (1.37 - 19.35) 0.015 
Previous use of Fludarabine 4.61 (1.45 - 14.69) 0.010 
Previous use of Melphalan 7.29 (3.37 - 15.79) <0.001 
Previous use of Lenalidomide   
 Absent 0.43 (0.28 - 0.68) <0.001 
 ≤ 4 cycles 2.25 (1.42 - 3.57) 0.001 
 >4 cycles 2.55 (0.49 - 13.22) 0.266 
At least one treatment at risk 2.93 (1.98 - 4.35) <0.001 
Previous radiotherapy   
 Absent 0.89 (0.55 - 1.43) 0.623 
 Limited 1.1 (0.65 - 1.87) 0.711 
 Extensive 
 (on marrow bearing tissue) 1.18 (0.45 - 3.09) 0.743 
Previous mobilization failure 6.36 (4.08 - 9.9) <0.001 
Disease remission (CR or PR) before 
mobilization 1.96 (1.37 - 2.81) <0.001 
Pre-mobilization BMB   
 Absent 0.74 (0.54 - 1.02) 0.066 
 <30% 1.04 (0.71 - 1.54) 0.828 
 ≥ 30% 3.02 (1.45 - 6.28) 0.003 
 Notdone 1.2 (0.79 - 1.83) 0.392 
CBC before mobilization   
 Hemoglobin (10 g/L) 0.81 (0.74 - 0.9) <0.001 
 Leukocytes (10-fold) 0.31 (0.18 - 0.55) <0.001 
 Neutrophils (10-fold) 0.39 (0.24 - 0.64) <0.001 
 Platelets (1 x 109/L) 0.996 (0.994 – 0.997) <0.001 
Priming strategy   
 CTX 3-7 g/m2 + G-CSF 0.78 (0.57 - 1.07) 0.118 
 DHAP or DHAOx  + G-CSF 0.58 (0.31 - 1.1) 0.094 
 IEV + G-CSF 0.58 (0.25 - 1.36) 0.208 
 High-dose Ara-C + G-CSF 0.95 (0.53 - 1.7) 0.857 
 Other chemotherapy + G-CSF 0.97 (0.66 - 1.42) 0.865 
 G-CSF alone 5.43 (3.31 - 8.9) <0.001 
Type of G-CSF   
 Lenograstim 0.9 (0.65 - 1.25) 0.536 
 Filgrastim 1.23 (0.9 - 1.69) 0.197 
 Pegfilgrastim 1.47 (0.41 - 5.2) 0.553 
 Biosimilar 0.79 (0.18 - 3.46) 0.752 
 Missing data 0.63 (0.32 - 1.23) 0.179 
Double G-CSF dose (vs standard) 1.02 (0.73 - 1.43) 0.918 
Upfront plerixafor 2.47 (1.25 - 4.89) 0.010 
 
Table IV: Independent predictive factors for mobilization failure identified by backward variable selection 
with multiple logistic regression on significance level 0.1 for the Wald statistic 
Predictive factor β Odds ratio (95% CI) Probability (Wald test) 
Age class (46-60 years = 1; > 60 years = 2) 0.3796 1.46 (1.14 - 1.88) 0.003 
Diagnosis = NHL 0.5535 1.74 (1.16 - 2.6) 0.007 
Disease infiltration ≥ 30% at the pre-mobilization BMB 1.269 3.56 (1.51 - 8.35) 0.004 
Number of full chemotherapy courses 0.5888 1.8 (1.43 - 2.27) <0.001 
At least one previous treatment at risk 0.7739 2.17 (1.28 - 3.67) 0.004 
Pre-mobilization Hb value class (<80 g/l = 1; 80 – 130 g/l = 2) 1.1165 3.05 (1.72 - 5.42) <0.001 
Pre-mobilization WBC < 5 x 109/L 0.7185 2.05 (1.41 - 2.99) <0.001 
Pre mobilization Plt< 170 x 109/L 0.5869 1.8 (1.23 - 2.62) 0.002 
Priming with G-CSF alone 2.2513 9.5 (4.75 - 19) <0.001 
Upfront Plerixafor not planned 2.7292 15.32 (5.09 - 46.16) <0.001 
Previous mobilization failure 1.9059 6.73 (3.67 - 12.34) <0.001 
 
Table V. Calculation of predicted Poor Mobilizer (pPM) and simplified predicted Poor Mobilizer (s-PPM )score 
 
 
pPM score Simplified pPM score 
0.3796 (if age 46-60 years) 
+ 0.7592 (if age > 60 years) 
+ 0.5535 (if diagnosis NHL) 
+ 1.269 (if disease infiltration ≥ 30% at the pre-
mobilization BMB) 
+ 0.5888 x [number of full chemotherapy courses] 
+ 0.77388929 (if one previous treatment at risk) 
+ 1.1165 (if Hb 80 – 130 g/l) 
+ 2.233 (if Hb < 80 g/l) 
+ 0.7185 (if WBC count < 5 x 109/L) 
+ 0.5869 (if Plt < 170 x 109/L) 
+ 2.251 (if priming with G-CSF alone) 
+ 2.7292 (if upfront Plerixafor not planned) 
+ 1.906 (if previous mobilization failure) 
0.5 (if age > 60 years) 
+ 0.5 (if diagnosis NHL) 
+ 1 (if disease infiltration ≥ 30% at the pre-
mobilization BMB) 
+ 0.5 x [number of full chemotherapy courses] 
+ 0.5 (if one previous treatment at risk) 
+ 1 (if Hb 80 – 130 g/l) 
+ 2 (if Hb < 80 g/l) 
+ 0.5 (if WBC count < 5 x 109/L) 
+ 0.5 (if Plt < 170 x 109/L) 
+ 2 (if priming with G-CSF alone) 
+ 2 (if upfront Plerixafor not planned) 
+ 1.5 (if previous mobilization failure) 
 
Table VI: Bootstrap validation according to Efron et al. 
Apparent area under the ROC curve 0.8014
Mean AUC of 10.000 bootstrap samples 0.8066 
Mean AUC of 10.000 tests in original database 0.7959 
Optimism in apparent performance 0.0107 
Optimism-corrected AUC 0.7907
 
Table 7. The pPM score can be used to tailor SCM strategy from baseline, unmodifiable risk factors: here we describe examples of calculation of pPM score in 
10 different clinical scenarios; we also report suggested SCM strategies based on changes of pPM score due to different clinical choices. 
Category of patients Baseline 
pPM 
score 
Suggested SCM strategy pPM 
score 
Predicted 
probability of 
failure 
Other 
suggestions 
Low risk  
MM with ≥ PR after 1st line (without lenalidomide), no 
cytopenias, even beyond 60y 
1 
Cytokine-only (+2) 
No upfront PLX (+2) 
5 <15% Tailor collection 
according to 
target dose HL without significant BM involvement after 2nd line, <60y 1 5 <15% 
NHL without significant BM involvement after 1st line, <60y 1 5 <15% 
Intermediate risk
NHL without significant BM involvement after 1st salvage 
treatment, mild cytopenias*, > 60y 
3 
CHT-based SCM (0) 
No upfront PLX (+2) 
5 12-16% Careful SCM 
monitoring with 
prompt 
intervention (Plx 
on demand) 
MM with marrow plasmacytosis <30% after 2nd line with 
lenalidomide, mild cytopenias*, > 60y 
3 5 15-18% 
MM with marrow plasmacytosis <30% after 2nd line with 
lenalidomide, no cytopenias, after failed SCM attempt, > 60y 
3.5 Cytokine-only (+2) 
Upfront PLX (0) 
5.5 <30% 
High risk  
NHL (no significant BM involvement) after 1st salvage 
treatment, after failed SCM attempt, mild cytopenias*, > 60y
4.5 CHT-based SCM (0) 
No upfront PLX (+2) 
6.5 50% On demand Plx (if 
not planned 
upfront) 
 
Use of large 
volume apheresis
 
Start apheresis 
with lower CD34+ 
threshold 
CHT-based SCM (0) 
Upfront PLX (0) 
4.5 <10%** 
MM with marrow plasmacytosis >30% after 2nd line with 
lenalidomide, trilinear cytopenias, > 60y 
5 CHT-based SCM (0) 
No upfront PLX (+2) 
7 71% 
CHT-based SCM (0) 
Upfront PLX (0) 
5 <15%** 
NHL (no significant BM involvement) after 2nd salvage 
treatment (of which one at risk), trilinear cytopenias, > 60y 
5 CHT-based SCM (0) 
No upfront PLX (+2) 
7 68% 
CHT-based SCM (0) 
Upfront PLX (0) 
5 <15%**
MM: Multiple Myeloma; NHL: Non-Hodgkin Lymphoma; HL: Hodgkin Lymphoma; SCM: Stem-cell mobilization; BM: Bone marrow; PLX: Plerixafor. * Either 
Hb<13 g/dl or Plt<170.000/mmc and WBC<5000/mmc. ** Concurrent use of upfront Plx and chemo-based SCT was not frequent in our sample and thus the 
reported probability may be inaccurate 
